Pfizer Inc.’s next-generation treatment for breast cancer posted mixed results in a final-stage study, a potential setback ...

Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on the horizon. Pfizer—the maker of Paxlovid—has begun Phase 3 ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

However, its potential is seen as being tied to the ability of the drug to target the broader population of ESR1 'wild-type' patients While Pfizer trumpeted the result as a "clinically meaningful ...

Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

The Maryland Senate voted to allow a state board to extend its mandate for lowering prescription drug costs to all residents.

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...

Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...